Page 19 - Labatt Brain Tumour Research Centre Annual Report 2022 to 2023

Improving therapy by targeting the biological differences between micro- and macro-metastasis in central nervous system tumors. Matthew Larson Foundation
Novel therapeutic targets for group 3 medulloblastoma stem cells. Canadian Institutes of Health Research
Immunotherapeutic targeting of a novel spliceosomal RNA mutation in cancer. Canadian Institutes of Health Research
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma. National Institutes of Health
Combining epigenetic therapy and immunotherapy to target group 4 medulloblastoma. Children’s Health Research Institute – Goldstein gift
Probing the developmental origins of pediatric cerebellar brain cancers using single cell profiling. Canadian Institutes of Health Research
Identifying a drug that actually works for PFA ependymoma. b.r.a.i.n.child
Dr. Vijay Ramaswamy
Molecular and functional characterization of childhood ependymoma. Canadian Institutes of Health Research
SubINT PP Costs Phase I/lb trial of combined 5’azacitidine and carboplatin for recurrent/refractory pediatric brain and solid tumors and recurrent
or refractory ependymoma. Ontario Institute for Cancer Research
Unravelling the DNA damage response. SickKids Foundation
Characterizing mechanisms of treatment resistance in very high-risk medulloblastoma. Meagan’s HUG (Meagan Bebenek Foundation)
Genomic determinants of outcome in high-risk medulloblastoma of infancy. b.r.a.i.n.child
Dr. James Rutka
Molecular therapeutic targeting of malignant gliomas. Canadian Institutes of Health Research
Enhancing the delivery of novel chemotherapeutics to diffuse intrinsic pontine glioma. Canadian Institutes of Health Research
Precision medicine approaches to treating diffuse intrinsic pontine gliomas. Meagan’s HUG (Meagan Bebenek Foundation)
Dr. Gelareh Zadeh
Uncovering the molecular biomarkers of radiation responsiveness in meningiomas. Canadian Institutes of Health Research
Proteomic markers of treatment-induced adaptation to hypoxia in glioblastoma. Cancer Research Society
Establishing the clinical utility of cell-free tumor DNA methylation profiling as a reliable liquid biopsy approach in brain tumors. National Cancer Institute (USA)
The utilization of cell-free DNA methylation signatures in cerebrospinal fluid for diagnosis and early detection of progression in glioblastoma and brain metastases. University of Toronto – McLaughlin Centre
Uncovering the oncogenic potential of CIC-fusions and JAK/STAT1/3 activation in CIC rearranged sarcomas. Cancer Research Society
Liquid biopsy-based DNA methylation profiling for improved diagnosis and prognostication of primary and metastatic CNS tumor. Canadian Institutes of Health Research
Created in 1999, the dove, symbolizing hope, is carrying a twig in its beak. The twig is actually a piece of double- stranded DNA representing molecular medicine. Together, they symbolize the mandate of the BTRC: Hope through molecular medicine.
19
W